
Full name:30;
Full Address:11119 North Torrey Pines Road Suite 125 La Jolla, CA 92037 United States 858-500-8800 http://www.kuraoncology.com;
Sector:;
Industry:;
Market Cap: 492.514MB;

Description:
 Kura Oncology, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of cancers. Itspipeline consists of small molecule product candidates that target cancer. The companyÂ’s lead product candidate isTipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors,peripheral T-cell lymphomas, lower risk myelodysplastic syndromes, and chronic myelomonocytic leukemia. It also developsKO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment for patients withtumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a smallmolecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in La Jolla,California.;

Fiscal Year:2016;
Total Revenue:0;
Net Revenue:-27560;
Total Assets:69821;

Fiscal Year:2015;
Total Revenue:0;
Net Revenue:-22625;
Total Assets:87259;

Fiscal Year:2014;
Total Revenue:0;
Net Revenue:-30.734;
Total Assets:1378;


